The FDA has put Progenics' HIV therapy PRO 140 on its fast track review program. The therapy is one of a new class of HIV/AIDS drugs that are designed to protect healthy cells from infection by targeting a molecular portal with a humanized monoclonal antibody.
"Fast-track status has the potential to accelerate the development of PRO 140," said Paul J. Maddon, M.D., Ph.D., Tarrytown, NY-based Progenics' CEO and chief science officer. "Although great strides have been made in HIV treatment, there is an urgent need for the development of new therapies such as PRO 140 to address the limitations of currently available HIV drugs."
- read this AP report for more
ALSO: The FDA has granted Schering-Plough a priority review for the anti-fungal Noxafil. Report